Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [1][4] - Haduvio acts on the cough reflex arc as a kappa agonist and mu antagonist, targeting opioid receptors involved in cough hypersensitivity [1][4] Market Need - Chronic cough is prevalent among approximately 140,000 IPF patients in the U.S., with up to 85% experiencing this symptom, leading to significant health impacts [2] - Patients with chronic cough may cough up to 1,500 times per day, which can worsen their disease and increase the risk of progression, death, or the need for lung transplants [2] - There are currently no approved therapies for chronic cough in IPF, and existing off-label treatments offer minimal benefits [2] Refractory Chronic Cough - Refractory chronic cough affects around 2-3 million adults in the U.S., caused by cough reflex hypersensitivity [3] - This condition is disruptive and can lead to complications such as urinary incontinence, sleep disruption, and social embarrassment, imposing significant social and economic burdens [3] - Similar to chronic cough in IPF, there are no approved therapies for RCC in the U.S. [3] Upcoming Events - Trevi Therapeutics will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 1:00 p.m. ET, with additional investor meetings scheduled [1]